News 26.02.2021 Zurich-Schlieren, Switzerland, February 26, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published its audited Financial Results for 2020 and the company’s 2020 Annual Report. The Audited Financial Results for 2020 and the company’s...
Events, Internal events
Event date: 09.03.2021
12:00 - 12:45 Uhr, online (Zoom)
Ein Technopark-Allianz-Webinar
Referenten: Michael Baier, Legal, und Patric Eggler, Tax, bei Wenger & Vieli Rechtsanwälte.
Vorträge und Kurse zur Startup-Gründung gibt es zuhauf. Wenn es aber um den Verkauf, also um das Loslassen eines mit viel Energie aufgebauten Geschäfts geht, ist guter Rat oft teuer, und es sind viele Fallgruben...
News 05.02.2021 Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included potential total cash consideration of CHF 215 million, comprised of an upfront payment, equity purchase, and...
News 04.02.2021 Zurich-Schlieren, Switzerland, February 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced results from a study conducted at Spiez Laboratory. The study assessed leading SARS-CoV-2 anti-infective molecules, including...
News 14.01.2021 Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics. The leading...